WHO ICTRP trial
Study on the efficacy and safety of preoperative neoadjuvant immunotherapy in…
ChiCTR2300074425 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2300074425 |
|---|---|
| Public title | Study on the efficacy and safety of preoperative neoadjuvant immunotherapy in patients with primary resectable liver cancer with initial treatment |
| Scientific title | Study on the efficacy and safety of preoperative neoadjuvant immunotherapy in patients with primary resectable liver cancer with initial treatment |
| Primary sponsor | The First Affiliated Hospital of PLA Army Military Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Primary liver cancer |
| Interventions | Preoperative neoadjuvant immunotherapy group (neoadjuvant sindillizumab treatment group):Sintilimab injection (Sintilimab, Darbersol, is a recombinant fully human monoclonal antibody against programmed death receptor 1, specifications… |
| Registration date | Aug 7, 2023 |
| Target size | Preoperative neoadjuvant immunotherapy group (neoadjuvant sindillizumab… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: